CDC Narrows Age Recommendation for Use of RSV Vaccine
https://www.zacks.com/stock/news/2295178/cdc-narrows-age-recommendation-for-use-of-rsv-vaccine?cid=CS-ZC-FT-analyst_blog|industry_focus-2295178
Jun 28, 2024 - The U.S. CDC recommends that adults aged 75 years and above get an RSV shot. Those aged 60 to 74 years should only get the shot if they are at high risk for severe RSV due to chronic conditions.
0
Moderna (MRNA) Shares Decline on RSV Vaccine Efficacy Data
https://www.zacks.com/stock/news/2294523/moderna-mrna-shares-decline-on-rsv-vaccine-efficacy-data?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2294523
Jun 27, 2024 - Moderna (MRNA) stock sinks after new data shows the efficacy of its mRNA-based RSV vaccine fell sharply in the second year and was lower than that of rival vaccines marketed by GSK and Pfizer.
0
Here's Why GSK (GSK) is a Strong Value Stock
https://www.zacks.com/stock/news/2294282/here-s-why-gsk-gsk-is-a-strong-value-stock?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_value_score-2294282
Jun 27, 2024 - The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
0
GSK, Pfizer decline as CDC advisors recommend narrower age range for RSV shots
https://seekingalpha.com/news/4119818-gsk-pfizer-decline-cdc-advisors-recommend-narrower-age-range-rsv-shots?source=feed_sector_healthcare
Jun 26, 2024 - GSK and Pfizer stocks declined after CDC advisors did not recommend RSV vaccines below the age of 60. Read more here.
0
Top Stock Reports for Chevron, Amgen & Philip Morris
https://www.zacks.com/commentary/2292698/top-stock-reports-for-chevron-amgen-philip-morris?cid=CS-ZC-FT-research_daily-2292698
Jun 25, 2024 - Today's Research Daily features new research reports on 16 major stocks, including Chevron Corporation (CVX), Amgen Inc. (AMGN) and Philip Morris International Inc. (PM), as well as two micro-cap stocks Hurco Companies, Inc. (HURC) and Perma-Pipe International Holdings, Inc. (PPIH).
0
GSK's Filing for Expanded Use of Jemperli Gets EMA Acceptance
https://www.zacks.com/stock/news/2292155/gsk-s-filing-for-expanded-use-of-jemperli-gets-ema-acceptance?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2292155
Jun 24, 2024 - The European Medicines Agency accepts GSK's application for the expanded use of Jemperli plus chemotherapy to include all adult patients with primary advanced or recurrent endometrial cancer.
0
Myriad Genetics (MYGN) and GSK Unite to Boost HRD Testing
https://www.zacks.com/stock/news/2287420/myriad-genetics-mygn-and-gsk-unite-to-boost-hrd-testing?cid=CS-ZC-FT-analyst_blog|company_news_medical_sector-2287420
Jun 12, 2024 - Myriad Genetics (MYGN) collaborates with GSK to improve access to HRD diagnostic testing for HGSOC patients.
0
Why GSK (GSK) is a Top Value Stock for the Long-Term
https://www.zacks.com/stock/news/2286596/why-gsk-gsk-is-a-top-value-stock-for-the-long-term?cid=CS-ZC-FT-tale_of_the_tape|zacks_education_value_score-2286596
Jun 11, 2024 - The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
0
GSK wins FDA nod to expand label for RSV vaccine
https://seekingalpha.com/news/4114295-gsk-wins-fda-nod-expand-rsv-vaccine-label?source=feed_sector_healthcare
Jun 08, 2024 - GSK (GSK) obtains FDA approval to expand label for its RSV vaccine, Arexvy for adults aged 50–59 years. Read more here.
0
FDA approves GSK's RSV vaccine for high-risk adults ages 50 to 59, expanding shot's reach
https://www.cnbc.com/2024/06/07/fda-approves-gsk-rsv-vaccine-for-adults-50-to-59.html
Jun 07, 2024 - The FDA's expanded approval could help GSK maintain its dominance in the RSV market, which includes shots from Pfizer and Moderna.
0